Status:
COMPLETED
High Dosage Esomeprazole and Baclofen for Therapy of Gastroesophageal Reflux Disease
Lead Sponsor:
Technical University of Munich
Conditions:
Patients With Persistent Objectified Gastroesophageal Reflux and Reflux-Associated Symptoms Despite PPI-Therapy With 40mg Esomeprazole
Eligibility:
All Genders
18-70 years
Brief Summary
It has been reported that Baclofen is an appropriate tool in the therapeutic management of Gastroesophageal Reflux Disease. To objectify gastroesophageal reflux combined pH-metry/impedance monitoring ...
Eligibility Criteria
Inclusion
- age between 18-70 years
- informed consent
- patients with persistent reflux-associated symptoms despite PPI-therapy
Exclusion
- epilepsy
- synthetic liver diseases
- renal failure
- disability to understand informed consent
Key Trial Info
Start Date :
October 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2008
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00461604
Start Date
October 1 2006
End Date
May 1 2008
Last Update
May 20 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Technical University of Munich
Munich, Bavaria, Germany, 81675